2026

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates